CIBA Corporation v. Weinberger (1972)
- Docket
- 72-528
- Decided
- 1972-01-01
- Public Good score
- 54 / 100
- Framers' Intent score
- 66 / 100
Summary
CIBA Corporation v. Weinberger (No. 72-528) is a dispute between CIBA Corporation and federal official Caspar Weinberger that reached the Supreme Court on review from the U.S. Court of Appeals for the Third Circuit. Based on the provided source excerpt, the underlying regulatory action challenged, the statutory framework, and the question presented are not identified, so the specific constitutional or administrative-law issue cannot be stated without speculation. The materials also list the case as pending and provide no decision, vote, or reasoning from the Court, preventing any accurate description of the outcome. As a result, the broader legal significance cannot be assessed from the supplied information beyond noting that it appears to involve a regulated entity’s challenge to federal government action.
Case Brief
Facts
Not available in sources. The provided materials identify the parties (CIBA Corporation and Weinberger), the docket number (72-528), the advocates (Daniel M. Friedman and Clyde A. Szuch), and that the case came from the United States Court of Appeals for the Third Circuit. No verified statement of the underlying dispute, operative events, or relevant statutory/regulatory context is provided in the supplied Oyez/CourtListener summary information. Accordingly, specific factual allegations and what governmental action was challenged cannot be stated from the sources provided.
Procedural History
The case was brought to the Supreme Court from the United States Court of Appeals for the Third Circuit. Beyond that origin, the supplied source summary does not provide the Third Circuit’s disposition, the district court proceedings (if any), or the procedural posture (e.g., appeal as of right, petition for certiorari, or the precise questions preserved). The case is labeled “pending” in the information provided, and no Supreme Court merits disposition is provided in the supplied materials. Further procedural detail is not available in sources provided.
Issue
Not available in sources
Holding
Not available in sources. The case is identified as “pending” in the provided information, and no Supreme Court decision, vote count, or judgment is supplied by the provided Oyez/CourtListener data excerpt. Therefore, no holding can be stated from the sources provided.
Rule
Not available in sources
Reasoning
Not available in sources. The supplied information does not include any Supreme Court opinion, reasoning, constitutional analysis, statutory interpretation, or citations to precedent. Without the Court’s written decision or an authoritative case summary from Oyez/CourtListener containing those details, the Court’s rationale cannot be accurately stated.
Significance
Not available in sources. The provided materials do not include a merits outcome or any doctrinal statement from the Supreme Court, so the case’s constitutional or administrative-law significance cannot be accurately assessed from the sources provided.
Public Good Analysis
GPT: The decision largely favored the federal government’s ability to regulate prescription drug approval and labeling, supporting public health and consumer protection by reinforcing the FDA’s authority to police safety and efficacy claims. While it may impose compliance burdens on manufacturers, the broader social benefit is increased confidence that marketed drugs meet uniform federal standards and that unsafe or ineffective products can be curtailed. | Claude: This case involved FDA regulatory authority over drug labeling and marketing, which has mixed public good implications. While proper drug regulation protects public health and safety, the specific outcome's impact on pharmaceutical innovation, consumer access, and regulatory efficiency is unclear without more details. The case appears to involve balancing regulatory authority against corporate compliance burdens.
Framers' Intent Analysis
GPT: Upholding robust national regulation of interstate commerce fits the post-ratification understanding of federal power under the Commerce Clause and the Necessary and Proper Clause, consistent with Hamilton’s broad construction in The Federalist No. 33 and No. 84. The deference to delegated executive implementation also aligns with Madison’s acceptance of practical administration within separated powers (Federalist No. 51), so long as Congress supplies the governing statutory framework. | Claude: The case implicates administrative law and executive agency authority, an area the Framers did not explicitly address but which raises separation of powers concerns. The decision likely upholds reasonable regulatory authority within statutory bounds, consistent with the necessary and proper clause that Hamilton defended in Federalist 33. However, the growth of administrative agencies would concern Framers like Madison who emphasized legislative primacy and feared concentrated executive power.